Introduction
============

*Klebsiella pneumoniae* is a Gram-negative bacterium, causing various fatal infections. There are 2 pathotypes: hypervirulent (hvKp) and classical (cKp), which are detrimental to our health. Initially, a string test with a length \>5 mm was defined as hypermucoviscosity, which is a traditional unique hvKp trait, triggering aggressive invasive infection, such as bloodstream infection and pyogenic liver abscesses (PLAs) for immunocompetent ambulatory younger individuals with non-underlying diseases.[@b1-idr-11-1031]--[@b4-idr-11-1031] However, many studies do not agree with the definition of hvKp defined by hypermucoviscosity phenotype.[@b5-idr-11-1031],[@b6-idr-11-1031] The reason is that few hypermucoviscous *K. pneumoniae* (hmvKp) strains are associated with high virulence with in vitro and in vivo assays.[@b5-idr-11-1031],[@b6-idr-11-1031] Thus, using hvKp by hypermucoviscosity phenotype as the sole indicator of hvKp is not appropriate.[@b7-idr-11-1031],[@b8-idr-11-1031]

Until recently, aerobactin, the dominant siderophore, was regarded as a critical virulence factor for hvKp genetic background.[@b1-idr-11-1031],[@b8-idr-11-1031],[@b9-idr-11-1031] A multicenter study, focusing on middle-aged patients, first demonstrated the clinical and molecular characteristic of hvKp (defined as aerobactin positive) infection.[@b8-idr-11-1031] But data are limited on the elderly who may have various underlying diseases, nutrition status, and atypical manifestations, along with being infected with genotype hvKp.

Many previous studies have illustrated that hvKp is sensitive to most antibiotics, which is not frequently present in infection with cKp strains. But emerging multidrug resistance (MDR) hvKp, especially resistant to colistin and carbapenems, has been reported in China.[@b10-idr-11-1031]--[@b12-idr-11-1031] However, there are not enough adapted data on the elderly and the characteristics of antimicrobial-resistant hvKp infection.

Thus, for further investigation of the prevalence and antibiotic resistance of hvKp, we conducted a retrospective study in 2 teaching hospitals based on the genotype of hvKp, which was defined as aerobactin positive.

Materials and methods
=====================

Patients
--------

A retrospective study was conducted on 202 *K. pneumoniae* culture-positive patients diagnosed at Beijing Tsinghua Changgung Hospital and Chinese PLA General Hospital from June 2008 to July 2017. The definition of elderly was if the patient was ≥65 years. Duplicate isolates from the same patient were excluded. The clinical characteristics, including underlying disease, infection type, nutritional status, mortality in 30 days, and sequential organ failure assessment (SOFA), were collected. To recognize the host responsibility and nutritional status between the 2 pathotypes, white blood cell count (WBC) and neutrophil percentage (NEU%) were used as primary and rough inflammatory factors. To evaluate the nutrition status, we used total protein (TP) and albumin (ALB) as markers. The study was approved by the Chinese PLA General Hospital Ethics Committee, and the Guidelines for Human Experimentation (China) were followed through the whole study. Informed consent was not needed due to the retrospective nature of the study; additionally, the patient data accessed in this research was anonymous. Therefore, the Chinese PLA General Hospital Ethics Committee waived the need for consent.

*K. pneumoniae* strains
-----------------------

All isolates were stored at −80°C and previously identified by the API 20 NE system and the Vitek II system. Additionally, species identification was further confirmed by 16S rRNA gene sequencing. HvKp was defined as aerobactin positive. Hypermucoviscous phenotype was confirmed by string test as described previously.[@b13-idr-11-1031]

Antimicrobial susceptibility testing and phenotypic detection of ESBLs
----------------------------------------------------------------------

Antimicrobial susceptibility testing was conducted and the results were interpreted by 2017 Clinical and Laboratory Standards Institute (CLSI) guidelines. The antibiotics include amikacin, gentamicin, tobramycin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, ceftriaxone, ceftazidime, ciprofloxacin, levofloxacin, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole. ESBL was confirmed by agar dilution test using ceftazidime and cefotaxime combined with clavulanate according to the CLSI guidelines.[@b8-idr-11-1031] MDR strains were defined as resistant to ≥3 different antimicrobial categories.[@b14-idr-11-1031] Isolates that are resistant to both imipenem and meropenem are defined as carbapenems-resistant (CR) isolates.

Detection of virulence gene
---------------------------

Genomic DNA of all *K. pneumoniae* isolates was extracted. Virulence-associated genes (*rmpA, rmpA2, magA*, and *aerobactin*) and capsular serotype-specific (*cps*) genes (*K1, K2, K5, K20, K54*, and *K57*) were amplified by polymerase chain reaction (PCR).[@b8-idr-11-1031],[@b15-idr-11-1031]--[@b17-idr-11-1031] The primers are listed in [Table S1](#SD1-idr-11-1031){ref-type="supplementary-material"}.

Multilocus sequence typing (MLST) for *K. pneumoniae*
-----------------------------------------------------

Seven housekeeping genes (*gapA, mdh, phoE, tonB, infB, pgi*, and *rpoB*) were amplified by PCR following the protocol (<http://bigsdb.pasteur.fr/klebsiella/klebsiella.html>) ([Table S1](#SD1-idr-11-1031){ref-type="supplementary-material"}). Allelic profiling and sequence types (STs) determination were also confirmed on the aforementioned website. Moreover, to further analyze the relationship among different STs, phylogenetic analysis of spliced 7 housekeeping genes for frequency \>1 isolates and strains contributing to invasive infection and mortality was performed by the neighbor-joining method (MEGA 7.0).

Statistical analysis
--------------------

SPSS software (version 20.0; IBM Corporation, Armonk, NY, USA) was performed for data analysis. Measurement data were assessed as mean ± SD. The count data was analyzed as percentages. Continuous variables were analyzed by Student's *t*-tests and the Wilcoxon rank-sum tests. Categorical variables were analyzed by χ^2^ or Fisher's exact test. Univariate logistic regression analyses were performed for risk factor. To further analyze independent risk factors, a multivariable logistic regression analysis was conducted. All variables with *P* values of \<0.05 were included in the multivariate model. All tests were 2-tailed. *P*-value \<0.05 was considered significant.

Results
=======

Patient characteristics
-----------------------

A total of 202 *K. pneumoniae* culture-positive patients were diagnosed at the 2 hospitals from June 2008 to July 2017. A total of 96 (47.5%) isolates were hvKp and 121 (59.9%) were hmvKp. All the PLA patients (10 cases) were infected with hvKp. The main infection type distribution in hospital was pneumonia (146, 72.3%), while other infection types included urinary infection (42, 20.8%), invasive infection (37, 18.3%), and abdominal infection (26, 12.9%). Moreover, almost half of the patients (98, 48.5%) presented with sepsis, and 24 (11.9%) were diagnosed as septic shock. A total of 181 (89.6%) were males and 21 (10.4%) were females; the mean age was 84.43±7.84 years.

Clinical features: hvKp vs. cKp
-------------------------------

Clinical features are shown in [Table 1](#t1-idr-11-1031){ref-type="table"}. The mean age of the hvKp group was younger than the cKp group (83.24±7.35 vs. 85.5±8.14 years, *P*=0.039). Diabetes (72.9% vs. 48.1%; *P*=0.000) and digestive diseases (22.9% vs. 13.5%; *P*=0.046) were highly associated with the hvKp group as their underlying diseases. Compared with the cKp group, a significantly higher number of patients with the hvKp presented with invasive infections (30.2% vs. 7.5%; *P*=0.000), liver abscess (10.4% vs. 0%; *P*=0.000), other abscess (26.0% vs. 2.8%; *P*=0.035), septic shock (16.7% vs. 7.5%; *P*=0.045), pneumonia (79.2% vs. 66.0%; *P*=0.037), and abdominal infection (21.9% vs. 4.7%; *P*=0.000). However, the incidence rates of urinary infection (13.5% vs. 27.4%, *P*=0.016) and stomach tube indwelling (60.4% vs. 77.4%, *P*=0.009) were comparably lower in the hvKp group.

WBC (12.74±3.94 10^9^/L vs. 10.59±3.48 10^9^/L, *P*=0.000) and NEU% (78.70±8.02 vs. 75.60±8.50, *P*=0.003) of patients with hvKp, represented as host responsibility, were significantly higher than cKp group. However, patients infected with hvKp were more likely to have a poorer nutritional status in TP (64.74±5.42 vs. 62.83±6.32, *P*=0.023) and ALB (34.98±3.40 vs. 33.78±3.73, *P*=0.019). Moreover, although the mortality in 30 days (16.7% vs. 21.7%, *P*=0.366) was not significantly different, SOFA score in patients with hvKp was notably higher (6.79±2.88 vs. 4.93±2.59, *P*=0.000; [Table 1](#t1-idr-11-1031){ref-type="table"}).

Genetic and phenotype characteristics: hvKp vs. cKp
---------------------------------------------------

Previous studies confirmed that virulence-associated genes (*rmpA, rmpA2*, and *magA*) and *cps* genes (*K1, K2, K5, K20, K54*, and *K57*) are clustered in the hvKp group.[@b18-idr-11-1031]--[@b20-idr-11-1031] A significant difference was that *K1, K2, rmpA, rmpA2*, and *magA* were highly clustered in hvKp (*P*=0.000, respectively), and *K5, K20, K54*, and *K57* were not associated with hvKp (*P*=0.106, 0.627, 0.894, and 0.211, respectively). There was no strain in the cKp group with K5 ([Table 1](#t1-idr-11-1031){ref-type="table"}). It was strongly noted that hypermucoviscosity was highly associated with hvKp (*P*=0.000).

Antimicrobial resistance and prevalence of ESBL-producing *K. pneumoniae* isolates
----------------------------------------------------------------------------------

Most of the hvKp isolates were sensitive to most of the antibiotics, with the exception of ampicillin, imipenem, and meropenem ([Table 2](#t2-idr-11-1031){ref-type="table"}). All Kp strains were resistant to ampicillin. In the hvKp group, 24 strains (25.0%) were MDR. A total of 25 hvKp isolates were identified as ESBL-producing *K. pneumoniae* isolates, which were more common in the cKp group (53.8% vs. 26.0%, *P*=0.001). One CR-hvKp isolate existed in one of these 2 teaching hospitals. In another referral center, 10 CR-hvKp strains were detected. The detailed information for the 11 CR-hvKp strains is shown in [Table S2](#SD2-idr-11-1031){ref-type="supplementary-material"}.

Risk factors: hvKp vs. cKp
--------------------------

In this study, univariate regression analysis showed that diabetes (odds ratio \[OR\]=2.903), digestive diseases (OR=2.127), and hypermucoviscosity (OR=17.446) were notable risk factors for hvKp infection. However, indwelling stomach tube (OR=0.447) was a protective factor for hvKp infection. Moreover, multivariate analysis revealed that diabetes (OR=2.566) and hypermucoviscosity (OR=15.249) were independent risk factors for hvKp infections ([Table 3](#t3-idr-11-1031){ref-type="table"}).

Risk factors: CR-hvKp vs. non-CR-hvKp
-------------------------------------

Patients with surgery history within 1 month (OR=19.5) and catheterized tracheal catheter (OR=6.051) were closely associated with CR-hvKp. However, patients with diabetes (OR=0.256) were more likely to be infected with non-CR-hvKp. A history of surgery within the last 1 month is an independent risk factor for CR-hvKp infection (OR=15.999) ([Table 4](#t4-idr-11-1031){ref-type="table"}).

MLST genotypic analysis
-----------------------

Among the 202 *K. pneumoniae* isolates, no new ST was identified in MLST database. The most prevalent ST in this study was ST23 (n=28; 13.9%), followed by ST412 (n=10; 5.0%), ST37 (n=7; 3.5%), ST65 (n=6; 3.0%), ST11 (n=5; 2.5%), ST17 (n=5; 2.5%), ST2905 (n=5; 2.5%), and ST2906 (n=5; 2.5%). The aforementioned STs accounted for 35.1% (43/202) of the total strains. Among the primary STs, ST23 (24/28), ST412 (6/9), ST17(5/5), and ST65(3/6) were strongly associated with hvKp, while ST11(0/5), ST2905(1/5), ST2906(1/5), and ST37(2/7) were more common in the cKp group. The more common clone complexes (CCs) of the CR-hvKp group were CC23 (n=3) and CC17 (n=3). There is an important phenomenon in the phylogenetic tree that a branch clustered with ST347, ST595, ST1469, ST2905, and ST2906 contributed to poor prognosis death in 30 days, which should be paid more attention ([Figure 1](#f1-idr-11-1031){ref-type="fig"}).

Discussion
==========

To our knowledge, this is the first and biggest systematic study focusing on the elderly infected with hvKp in China. In this study, 59.9% of hvKp were identified as hypermucoviscous by string test, which was significantly different from a previous retrospective study conducted in a single center in China, with a prevalence of 33% in Beijing.[@b13-idr-11-1031] In addition, the incidence of hvKp (47.5%) in genetic background is also higher than the figure in the previous multicenter studies (37.8%).[@b8-idr-11-1031] It can be concluded that hvKp is emerging as the major pathotype for the elderly in the 2 hospitals, which should be paid more attention. The prevalent ST in 2 hospitals is the same: ST23. However, different hospitals isolated with ST23 are not highly associated with hvKp, which indicates that fully relying on STs to identify hvKp may be unreliable. Although the definition of hvKp is controversial, it is an objective marker, like plasmid type, biofilm producing, serotypes and the ability of trigger inflammatory factors that may be needed for further study to complement the real hypervirulence. Therefore, the prevalence of hvKp may be incorrectly estimated due to the lack of definite and objective diagnostic methods.

HvKp causes various severe infections, posing a serious threat to health. Various types of K-antigen have been reported,[@b17-idr-11-1031],[@b21-idr-11-1031],[@b22-idr-11-1031] with the more important elements in Asia being K1 and K2, which are the reason for severe infection. But they are not the unique trait for hvKp.[@b23-idr-11-1031],[@b24-idr-11-1031] MagA is not a specific virulence gene for hvKp isolates causing PLA,[@b25-idr-11-1031] but it is highly associated with *cps* K1.[@b22-idr-11-1031],[@b26-idr-11-1031] Moreover, the mutant isolate (knockout magA) could not show hmv phenotype.[@b27-idr-11-1031] RmpA/RmpA2 was proposed as a virulent factor in addition to magA and cps K1/K2.[@b16-idr-11-1031] Although *rmpA* is not an independent factor contributing to pyogenic liver abscess, it promotes capsule synthesis, which is associated with hypermucoviscous.[@b3-idr-11-1031],[@b16-idr-11-1031] Our results are consistent with a previous study: invasive infection (especially liver abscess), hypermucoviscosity, and mainly virulence factors (*K1, K2, rmpA*, and *magA* genes) are highly presented in hvKp group.[@b8-idr-11-1031] So, a better understanding of risk factors is essential to make interventions. Our results show that patients with diabetes are more likely to be infected with hvKp. Additionally, hypermucoviscosity is strongly associated with hvKp. In our study, patients with surgery history of \<1 month are an independent risk factor for CR-hvKp infection, which should be focused more on how to prevent infection. A previous study concluded that major histocompatibility complex variants, nutritional status, and gut microbiota are essential host factors to improve the understanding of the hypervirulence phenomenon.[@b7-idr-11-1031] Our results demonstrated that in the hvKp group, patients with better nutritional status are associated with a more severe SOFA score and more serious inflammation reaction. All aforementioned characteristics may be a potential marker for early and precise empirical interventions for the elderly with hvKp.

Previous studies have revealed that most hvKp and antimicrobial-resistant patterns were non-overlapping.[@b8-idr-11-1031],[@b13-idr-11-1031] In this study, most hvKp were sensitive to most of the aforementioned antibiotics. In the hvKp group, the number of MDR-hvKp (25.0%) and ESBL-hvKp (26.0%) is significantly higher compared to the previous study performed in the multicenter study, with a prevalence of 12.6%.[@b8-idr-11-1031] It is alarming that the number of elderly with MDR-hvKp infection is increasing. Moreover, 1 CR-hvKp isolate was detected in 1 hospital, where long-term patients were hospitalized. However, 10 CR-hvKp strains were detected in the other hospital, which was a referral center receiving patients from other hospitals and the community. Therefore, the incidence of CR-hvKp may be underestimated in this region. Thus, these data revealed that MDR-hvKp is emerging among the elderly. However, to confirm this conclusion, further investigation using a larger population is needed.

The CR-hvKp was not detected in nosocomial environment by routine nosocomial infection surveillance. In addition, the 2 hospitals did not apply the use of anal swab for monitoring nosocomial infection. It is unclear whether gut microbiota composed of hvKp contributed to the infection. Thus, it is essential to enhance hospital infection surveillance for the elderly. A previous study suggested that wards previously infected with CR-hvKp should be disinfected and left unoccupied for \>2 weeks.[@b10-idr-11-1031] Otherwise it may be a good site for a fatal outbreak of the organism.

There are some limitations in our study. First, it was a retrospective study in 2 teaching hospitals for over 10 years. Most key inflammatory and nutrition status marker were not achieved. Second, in vitro and in vivo experiments as objective evidence, such as *Galleria mellonella*, mouse, or human neutrophil assay, may be needed to identify the real virulent Kp. Third, to further explore the pathogen genomic characteristics, especially for virulent and antibiotic-resistant environment, whole genome sequencing, transcriptomics, and proteomics may be needed. A larger prospective multicenter study, focusing on host, pathogen, and host--pathogen interaction (inflammatory factor), is needed to better defining the hvKp strains.

Conclusion
==========

The prevalence of hvKp may be higher than expected in the elderly. The epidemiology for hvKp in different hospitals is different. Although the definition of hvKp is still controversial, hvKp (aerobactin positive) strains were more likely to cause serious infections, such as liver abscess and septic shock, and more severe inflammatory reaction in the host. To further understand hvKp, host, pathogen, and host--pathogen interaction may be taken into consideration. The emerging MDR-hvKp, especially CR-hvKp, will be a great challenge for treatment. It is essential to enhance clinical awareness and management for the different types of hvKp infections.

Supplementary materials
=======================

###### 

Primers

  Name           Sequence
  -------------- --------------------------------
  *rmpA*         
   Forward       5-ACTGGGCTACCTCTGCTTCA-3
   Reverse       5-CTTGCATGAGCCATCTTTCA-3
  *rmpA2*        
   Forward       5-CTTTATGTGCAATAAG-GATGTT-3
   Reverse       5-CCTCCTGGAGAGTAAGCATT-3
  *magA*         
   Forward       5-GGTGCTCTTTACATCATTGC-3
   Reverse       5-GCAATGGCCATTTGCGTTAG-3
  *aerobactin*   
   Forward       5-GCATAGGCGGATACGAACAT-3
   Reverse       5-CACAGGGCAATTGCTTACCT-3
  *K1*           
   Forward       5-GTAGGTATTGCAAGCCATGC-3
   Reverse       5-GCCCAGGTTAATGAATCCGT-3
  *K2*           
   Forward       5-GGAGCCATTTGAATTCGGTG-3
   Reverse       5-TCCCTAGCACTGGCTTAAGT-3
  *K5*           
   Forward       5-GCCACCTCTAAGCATATAGC-3
   Reverse       5-CGCACCAGTAATTCCAACAG-3
  *K20*          
   Forward       5-CCGATTCGGTCAACTAGCTT-3
   Reverse       5-GCACCTCTATGAACTTTCAG-3
  *K54*          
   Forward       5-CATTAGCTCAGTGGTTGGCT-3
   Reverse       5-GCTTGACAAACACCATAGCAG-3
  *K57*          
   Forward       5-CGACAAATCTCTCCTGACGA-3
   Reverse       5-CGCGACAAACATAACACTCG-3
  *rpoB*         
   Forward       5-GGCGAAATGGCWGAGAACCA-3
   Reverse       5-GAGTCTTCGAAGTTGTAACC-3
  *gapA*         
   Forward       5-TGAAATATGACTCCACTCACGG-3
   Reverse       5-CTTCAGAAGCGGCTTTGATGGCTT-3
  *mdh*          
   Forward       5-TGAAATATGACTCCACTCACGG-3
   Reverse       5-CTTCAGAAGCGGCTTTGATGGCTT-3
  *pgi*          
   Forward       5-GAGAAAAACCTGCCTGTACTGCTGGC-3
   Reverse       5-CGCGCCACGCTTTATAGCGGTTAAT-3
  *phoE*         
   Forward       5-ACCTACCGCAACACCGACTTCTTCGG-3
   Reverse       5-TGATCAGAACTGGTAGGTGAT-3
  *infB*         
   Forward       5-CTCGCTGCTGGACTATATTCG-3
   Reverse       5-CGCTTTCAGCTCAAGAACTTC-3
  *tonB*         
   Forward       5-CTTTATACCTCGGTACATCAGGTT-3
   Reverse       5-ATTCGCCGGCTGRGCRGAGAG-3

###### 

Detailed clinical and microbiological features of CR-hvKp strains

  Clinical features            P1                                       P2                     P3                        P4                                             P5                                             P6                                P7                                             P8                                             P9                                             P10                                            P11
  ---------------------------- ---------------------------------------- ---------------------- ------------------------- ---------------------------------------------- ---------------------------------------------- --------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Age (years)                  87                                       87                     87                        88                                             79                                             71                                65                                             65                                             77                                             84                                             94
  Gender                       F                                        M                      M                         F                                              M                                              F                                 F                                              M                                              M                                              M                                              M
  Clinical department          Internal medicine                        Emergency              General surgery           ICU                                            General surgery                                ICU                               ICU                                            Thoracic surgery                               ICU                                            Thoracic surgery                               Respiratory
  Main underlying diseases     Bone fracture; Cardiovascular diseases   Diabetes               Surgery with in 1 month   Cerebrovascular disease                        Cancer; Surgery with in 1 month                Cancer; Surgery with in 1 month   Diabetes; Cerebrovascular disease              Cancer                                         Cancer; Surgery with in 1 month                Surgery with in 1 month                        Cancer; Cerebrovascular disease; diabetes
  Tube                         CVC; Ureter                              Ureter; Stomach tube   None                      CVC; Ureter; Stomach tube; Tracheal catheter   CVC; Ureter; Stomach tube; Tracheal catheter   CVC; Ureter; Tracheal catheter    CVC; Ureter; Stomach tube; Tracheal catheter   CVC; Ureter; Stomach tube; Tracheal catheter   CVC; Ureter; Stomach tube; Tracheal catheter   CVC; Ureter; Stomach tube; Tracheal catheter   CVC; Ureter; Stomach tube; Tracheal catheter
  Specimen type                Sputum                                   Sputum                 Pyogenic fluids           Bile                                           Sputum +Blood +Wound                           Bile+Blood                        Sputum+Urine +Feces                            Sputum                                         Pyogenic fluids                                Sputum+Urine                                   Drainage liquid
  Infection type               Pneumonia                                Pneumonia              Abscess                   PLA                                            Sepsis                                         Septic shock                      Septic shock                                   Sepsis                                         Septic shock                                   Septic shock                                   Sepsis
  WBC(10^9^/L)                 12.21                                    10.85                  13.76                     16.44                                          8.80                                           15.49                             10.0                                           18.32                                          11.66                                          9.51                                           4.64
  NEU (%)                      75.1                                     86.6                   92.5                      82.2                                           56.8                                           83.4                              69.9                                           87.4                                           88.0                                           65.2                                           68.3
  TP (g/L)                     79.4                                     60.5                   69.4                      52.8                                           54.7                                           49.6                              59                                             70.9                                           62                                             67.4                                           61.2
  ALB (g/L)                    40.3                                     27.7                   34.6                      28.2                                           20.6                                           30.0                              32.6                                           36.4                                           27.4                                           31.7                                           35.0
  Sensitive antibiotics        N                                        N                      N                         N                                              GEN; LEV; TOB                                  N                                 SMZ; TOB; AMK                                  SMZ                                            N                                              N                                              SMZ; AMK
  SOFA score                   6                                        10                     2                         13                                             7                                              9                                 7                                              4                                              5                                              6                                              7
  Empiric therapy              CIP+CAZ                                  CIP+CAZ                IPM                       IPM+ISE                                        IPM+MXF                                        CIP+CAZ                           IPM+ISE                                        IPM                                            IPM                                            MXF                                            MEM
  Switched therapy             MEM+TGC                                  MEM+TGC                TGC                       TGC                                            GEN+LEV                                        TGC+MEM                           TGC+MEM+FOS                                    TGC+MEM                                        TGC+MEM                                        TGC+MEM+FOS                                    TGC
  Clinical outcome             Survived                                 Survived               Survived                  Survived                                       Survived                                       Survived                          Survived                                       Died                                           Survived                                       Survived                                       Survived
  String test                  \+                                       \+                     \+                        \+                                             \+                                             \+                                \+                                             −                                              −                                              \+                                             \+
  Virulence-associated genes                                                                                                                                                                                                                                                                                                                                                                                                                         
   *rmpA*                      \+                                       \+                     \+                        \+                                             \+                                             \+                                \+                                             −                                              −                                              \+                                             \+
   *rmpA2*                     \+                                       \+                     \+                        \+                                             \+                                             \+                                \+                                             −                                              −                                              \+                                             \+
   *magA*                      \+                                       \+                     \+                        \+                                             \+                                             \+                                \+                                             −                                              \+                                             \+                                             \+
  *cps* genes                                                                                                                                                                                                                                                                                                                                                                                                                                        
   *K1*                        \+                                       −                      −                         \+                                             \+                                             \+                                \+                                             −                                              −                                              \+                                             −
   *K2*                        \+                                       \+                     \+                        \+                                             \+                                             \+                                \+                                             −                                              −                                              \+                                             −
   *K5*                        −                                        −                      −                         −                                              −                                              −                                 −                                              \+                                             \+                                             −                                              −
   *K20*                       −                                        \+                     −                         −                                              \+                                             −                                 −                                              −                                              \+                                             −                                              −
   *K54*                       −                                        −                      −                         −                                              −                                              −                                 \+                                             −                                              −                                              −                                              −
   *K57*                       \+                                       −                      −                         −                                              −                                              \+                                −                                              −                                              −                                              −                                              −
  MLST genotyping              23                                       23                     17                        17                                             347                                            17                                2905                                           2906                                           23                                             412                                            2874

**Abbreviations:** ALB, albumin; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; CVC, central venous catheter; F, female; FOS, fosfomycin; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; ISE, isepamicin; LEV, levofloxacin; MLST, multilocus sequence typing; M, male; MEM, meropenem; Mo, month; MXF, moxifloxacin; NEU, neutrophils; N, no; PLA; pyogenic liver abscess; SMZ, sulfamethoxazole; SOFA, sequential organ failure assessment; TGC, tigecycline; TOB, tobramycin; TP, total protein; TZP, piperacillin tazobactam; WBC, white blood cell; Y, yes; +, positive; −, negative.

We thank the team of curators of the Institut Pasteur MLST and whole genome MLST databases for curating the data and making them publicly available at <http://bigsdb.pasteur.fr>. Additionally, we thank Huicheng Wang for statistics, who works in China Food and Drug Administration. This work was supported by the China Postdoctoral Science Foundation (grant number 2014M562610) and the Excellent Young Program of the Organization Department of Beijing Municipal Party Committee (grant number 2016000057592G258).

**Disclosure**

The authors report no conflicts of interest in this work.

![Neighbor-joining dendrogram showing concatenated sequences of 7 housekeeping genes from the MLST database for the frequency \>1 STs and isolates contributing to invasive infection and mortality. Yellow solid rim represents death.\
**Abbreviations:** MLST, multilocus sequence typing; ST, sequence type.](idr-11-1031Fig1){#f1-idr-11-1031}

###### 

Clinical and microbiological features of hvKp

  Characteristic                 hvKp (N=96)      cKp (N=106)      *P*-value
  ------------------------------ ---------------- ---------------- -----------
  K serotype                                                       
   *K1*                          **33 (34.4%)**   **2 (1.9%)**     **0.000**
   *K2*                          **20 (20.8%)**   **2 (1.9%)**     **0.000**
   *K5*                          3 (3.1%)         0 (0%)           0.106
   *K20*                         6 (6.3%)         4 (3.8%)         0.627
   *K54*                         4 (3.8%)         3 (2.8%)         0.894
   *K57*                         10 (10.4%)       6 (6.3%)         0.211
  *rmpA*                         **76 (79.2%)**   **12 (11.3%)**   **0.000**
  *rmpA2*                        **68 (70.8%)**   **15 (14.2%)**   **0.000**
  *magA*                         **77 (80.2%)**   **50 (47.2%)**   **0.000**
  Hypermucoviscosity             **86 (89.6%)**   **35 (33.0%)**   **0.000**
  Basic demographics                                               
  Age                            **83.24±7.35**   **85.5±8.14**    **0.039**
  Male                           93 (96.9%)       88 (83.0%)       0.361
  Underlying diseases                                              
  Pulmonary disease              86 (89.6%)       85 (80.2%)       0.064
  Diabetes                       **70 (72.9%)**   **51 (48.1%)**   **0.000**
  Cardiovascular disease         45 (46.9%)       60 (56.6%)       0.167
  Cerebrovascular disease        15 (15.6%)       27 (25.5%)       0.085
  Cancer                         28 (29.2%)       27 (25.5%)       0.556
  Surgery within 1 month         14 (14.6%)       11 (10.4%)       0.365
  Digestive disease              **22 (22.9%)**   **13 (13.5%)**   **0.046**
  Catheter                                                         
  Central intravenous catheter   65 (67.7%)       66 (62.3%)       0\. 418
  Urinary catheter               73 (76.0%)       87 (82.1%)       0.291
  Tracheal catheter              34 (35.4%)       39 (36.8%)       0.839
  Stomach tube                   **58 (60.4%)**   **82 (77.4%)**   **0.009**
  Infection type                                                   
  Pneumonia                      **76 (79.2%)**   **70 (66.0%)**   **0.037**
  Urinary infection              **13 (13.5%)**   **29 (27.4%)**   **0.016**
  Invasive infection             **29 (30.2%)**   **8 (7.5%)**     **0.000**
   Bacteremia                    8 (8.3%)         4 (3.8%)         0.171
   Liver abscess                 **10 (10.4%)**   **0 (0%)**       **0.000**
   Other abscess                 **25 (26.0%)**   **3 (2.8%)**     **0.000**
  Abdominal infection            **21 (21.9%)**   **5 (4.7%)**     **0.000**
  Sepsis                         48 (50.0%)       50 (47.2%)       0.688
  Septic shock                   **16 (16.7%)**   **8 (7.5%)**     **0.045**
  Host responsibility                                              
  WBC (10^9^/L)                  **12.74±3.94**   **10.59±3.48**   **0.000**
  NEU%                           **78.70±8.02**   **75.6±8.50**    **0.003**
  Nutrition status                                                 
  TP                             **64.74±5.42**   **62.83±6.32**   **0.023**
  ALB                            **34.98±3.40**   **33.78±3.73**   **0.019**
  SOFA score                     **6.79±2.88**    **4.91±2.61**    **0.000**
  Infection occurred in ICU      19 (19.8%)       16 (15.1%)       0.378
  Mortality in 30 days           16 (16.7%)       23 (21.7%)       0.366

**Notes:** Data presented as mean ± standard deviation, unless otherwise stated. Bold values indicate *P*\<0.05.

**Abbreviations:** ALB, albumin; cKp, classic *Klebsiella pneumoniae*; ESBLs, extended-spectrum β-lactamases; hvKp, hypervirulent *Klebsiella pneumoniae*; ICU, intensive care unit; NEU%, neutrophil percentage; SOFA, sequential organ failure assessment; TP, total protein; WBC, white blood cell count.

###### 

Antibiotic resistance: hvKp vs. cKp

  Antibiotic agent                hvKp (N=96)   cKp (N=106)   *P*-value
  ------------------------------- ------------- ------------- -----------
  ESBLs                           25 (16.3%)    57 (40.0%)    0.000
  Amikacin                        10 (2.5%)     22 (11.6%)    0.044
  Gentamicin                      16 (8.8%)     41 (29.5%)    0.001
  Ampicillin/sulbactam            28 (20.0%)    60 (44.2%)    0.000
  Aztreonam                       18 (8.8%)     41 (23.2%)    0.002
  Cefazolin                       28 (18.8%)    59 (44.2%)    0.000
  Cefotetan                       14 (14.6%)    31 (29.2%)    0.012
  Cefepime                        15 (5.0%)     34 (14.7%)    0.006
  Ceftriaxone                     25 (16.3%)    51 (34.7%)    0.001
  Ceftazidime                     17 (7.5%)     43 (25.3%)    0.000
  Ciprofloxacin                   18 (10.0%)    43 (25.3%)    0.001
  Levofloxacin                    14 (6.3%)     40 (22.1%)    0.000
  Trimethoprim/sulfamethoxazole   15 (8.8%)     44 (34.7%)    0.000
  Piperacillin/tazobactam         13 (3.8%)     33 (13.7%)    0.003
  Imipenem                        11 (1.3%)     21 (2.1%)     0.104
  Meropenem                       12 (2.5%)     23 (2.1%)     0.085
  Tobramycin                      17 (8.8%)     39 (27.4%)    0.002

**Abbreviations:** cKp, classic *Klebsiella pneumoniae*; ESBLs, extended spectrum β-lactamase; hvKp, hypervirulent *Klebsiella pneumoniae*.

###### 

Risk factors for hvKp vs. cKp

  Variable                       Univariate OR (95% CI)           *P*-value   Multivariate OR (95% CI)         *P*-value
  ------------------------------ -------------------------------- ----------- -------------------------------- -----------
  Infection occurred in ICU      1.388 (0.668--2.884)             0.380                                        
  Male                           1.538 (0.608--3.888)             0.363                                        
  Hypermucoviscosity             **17.446 (8.079**--**37.673)**   **0.000**   **15.249 (6.905**--**33.875)**   **0.000**
  Pulmonary diseases             2.125 (0.945--4.779)             0.068                                        
  Diabetes                       **2.903 (1.610**--**5.236)**     **0.000**   **2.566 (1.258**--**5.235)**     **0.010**
  Cardiovascular disease         0.676 (0.388--1.179)             0.168                                        
  Cerebrovascular disease        0.542 (0.268--1.095)             0.088                                        
  Cancer                         1.205 (0.648--2.240)             0.556                                        
  Surgery within 1 month         1.475 (0.635--3.426)             0.367                                        
  Digestive diseases             **2.127 (1.004**--**4.505)**     **0.046**                                    
  Central intravenous catheter   1.271 (0.711--2.271)             0.419                                        
  Urinary catheter               0.693 (0.350--1.372)             0.293                                        
  Tracheal catheter              0.942 (0.530--1.673)             0.839                                        
  Stomach tube                   **0.447 (0.242**--**0.824)**     **0.010**                                    

**Note:** Bold values indicate *P*\<0.05.

**Abbreviations:** cKp, classic *Klebsiella pneumoniae*; hvKp, hypervirulent *Klebsiella pneumoniae*; ICU, intensive care unit; OR, odds ratio.

###### 

Risk factor for CR-hvKp vs. non-CR-hvKp

  Variable                       Univariate OR (95% CI)          *P*-value   Multivariate OR (95% CI)         *P*-value
  ------------------------------ ------------------------------- ----------- -------------------------------- -----------
  Hypermucoviscous               0.468 (0.086--2.550)            0.380                                        
  Infection occurred in ICU      2.667 (0.692--10.277)           0.154                                        
  Pulmonary diseases             3.879 (0.052--1.112)            0.162                                        
  Cancer                         2.246 (0.625--8.077)            0.215                                        
  Diabetes                       **0.256 (0.071**--**0.930)**    **0.038**                                    
  Cardiovascular disease         0.613 (0.167--2.250)            0.461                                        
  Cerebrovascular disease        3.884 (0.965--15.313)           0.056                                        
  Surgery within 1 month         **19.5 (4.567**--**83.265)**    **0.000**   **15.999 (3.412**--**75.026)**   **0.000**
  Digestive diseases             2.386 (0.662--8.602)            0.184                                        
  Central intravenous catheter   2.330 (0.472--11.501)           0.299                                        
  Tracheal catheter              **6.051 (1.485**--**24.658)**   **0.012**                                    
  Stomach tube                   1.867 (0.462--7.535)            0.381                                        
  Urinary catheter               3.492 (0.422--28.865)           0.246                                        

**Note:** Bold values indicate *P*\<0.05.

**Abbreviations:** cKp, classic *Klebsiella pneumoniae*; CR, carbapenems-resistant; hvKp, hypervirulent *Klebsiella pneumoniae*; ICU, intensive care unit; OR, odds ratio.
